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INTRODUC,TION
For many years gold compounds have been used reluctantly by clinicians treating
aggressive rheumatoid arthritis [1]. The reluctance stems from the fact that the
compounds are effective only in some patients and from the potential toxicity of gold in
vivo. Various alternatives have been suggested over the past 20 years and none have
proved sufficiently good to completely replace gold as a major contributor in the therapy
of rheumatoid arthritis. However, the in vivo chemistry of gold is extremely complex and
it may be possible to improve the therapeutic effectiveness of gold compounds through
an understanding of the chemistry. The discovery of an effective orally active gold
compound auranofin -led to comparative studies with the injectable drug myocrisin.
One clear conclusion to be reached was that the distribution and in vivo reactivity of the
two compounds was very different, suggesting that the optimum therapeutic-to-toxic
ratio could be significantly improved by a better targetted compound. The purpose of the
present article is to review work on the distribution and reactivity in vivo of gold following
injection with myocrisin. Some current investigations into possible modes of toxic and
therapeutic action are described.
DISTRIBUTION OF MYOCRISlN
Myocrisin is usually given as an intermuscular injection once a week. Small samples of
animal tissue taken from around the injection site show initially very high concentrations
of gold which gradually reduce with time. Following the initial injection, most myocrisin
diffuses to the plasma unchanged. However, within the first 12 hours, the majority
becomes bound to the proteins leaving only a very small amount of unbound material
[2]. The concentration of gold in each fraction varies somewhat depending on the
separation technique used. Where gel permeation chromatography has been used [3],
the gold is bound mainly to albumin with a smaller fraction bound to globulins. The main
binding site in albumin is known to be one specific reactive thiol group, cysteine-34, to
which gold complexes as gold(I) by an exchange reaction with the thiomalate ligand
present in myocdsin [4]. Similar results are obtained on separation by electrophoresis [2]
but the amount present in albumin is lower. In addition, in electrophoresis a small spot
appears on the strip above the proteins. The position of this spot corresponds almost
exactly to that of free myocrisin. The conclusion is that a small fraction of the gold
present in albumin is removed as myocrisin by electrophoresis. It leads to the suggestion
that some of the drug is loosely adsorbed onto the protein rather than complexed to a
specific site. This is not surprising in that albumin can transport a range of exogenous
molecules in hydrophobic or hydrophilic pockets.
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A common therapeutic regime employed in myocrisin therapy is a 12 week course of
once weekly injections of 50 mg of the drug. In such a treatment, the gold concentration
in the plasma accumulates in a saw tooth pattern [2]. Immediately following injection
there is an increase in the gold present in the blood stream. During the week, a
significant fraction of this gold is either adsorbed into tissues or excreted leaving a
smaller but appreciable fraction in the blood. Subsequent injections build on this base
and raise the gold level in the plasma. Thus, in the 12 week period the gold
concentration present in blood accumulates. The. final concentration is usually between
2 and 3 Ig per ml. This is regarded as an optimum level for therapy although them is no
general agreement on the value of the gold concentration in plasma in determining
effective treatment. Subsequently, a maintenance course of monthly injections is given
to maintain an acceptable gold level over a longer period of time.
An attempt has been made to follow the gold concentration in 10 patients with time [2].
Since these patients attended an out-patient clinic, it was not always possible to obtain
samples at the same time during therapy and all patients did not complete the course.
The separation was carried out by electrophoresis and the gold analysed by carbon
furnace atomic absorption spectrometry. The amount of gold removed from the plasma
proteins by electrophoresis and believed to be free myocrisin and the gold y-globulin
albumin ratio varied from patient to patient but in any one patient it did not change
significantly during the 12 week period despite the increasing gold plasma
concentration. These results suggest that there is no saturation of any one gold site and
indicate the ready formation in vivo of a gold-globulin complex as well as a gold-albumin
one. The fact that the distribution does not change much in any individual patient with
increasing gold level is not surprising. The sulphydryl concentration in the plasma due
principally to albumin is about 200-500 times larger than the gold concentration
achieved during therapy. Thus, there can be no saturation of the albumin site. Albumin
accounts for approximately half the protein mass in the plasma and y-globulin is an
appreciable fraction of the rest. As such, it is unlikely that any binding site on y-globulin
can be saturated at clinically relevant concentrations. It is possible that a protein present
at lower concentrations does have a saturated site, but none have been identified so far
and the presence of an excess of effective complexing sites would require very strong
complexing for saturation to occur.
During the process of circulation and accumulation in plasma, an appreciable fraction of
the gold transfers from plasma to the circulating cells [5]. The amount that transfers
varies from patient to patient. Much of it is present in the cell membrane with smaller
amounts in the cytosol. The amount in the cytosol varies. It is lower with myocrisin than
with auranofin and it is higher in patients who smoke. Recent papers have highlighted
the fact that smoking increases the amount of thiocyanate and cyanide in the blood
stream [6]. It may be that gold cyanide forms and transports the gold across the
membrane. Red cell gold concentrations do not appear to correlate with clinical
improvement and although they are higher in smokers, there appears to be no added
improvement in the disease among patients who are on myocrisin and who also smoke.
In the cytosol of red blood cells, appreciable fractions of the gold present binds to
haemoglobin and glutathione but there are other high molecular weight fractions (see
article by Tepperman and Elder [7]) suggesting that gold is bound to the functional
active extrinsic and intrinsic membrane proteins such as the hexose transporter [8] and
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spectrin [7]. Efforts have been made to carry out SDS page separations on cell
membrane derived from myocrisin treated erythrocytes. Them is evidence of a new
protein (~55kD) appearing following gold incubation [9]. Whether this results from a
breakdown of an existing protein or is a genuine new species is not known.
In white cells, using electron microscopy with chemical analysis, gold deposits can be
found around lysosomes and in small vesicles known as aurosomes [10]. These contain
a high concentration of both gold and sulphur. These groups are the most obvious in
electron micrographs and correspond to the highest concentrations of gold in specific
parts of the cell. Gold has been postulated to work by preventing the release of
lysosomal enzymes from the lysosomes in the cell and the grouping of these deposits in
a suitable area of the cell is cited as evidence in favour if this mechanism. However, in
cells, isolated vesicles containing metals can be used by the cell as a mechanism to
neutralise toxic species and the gold in the aurosome may be in unreactive and
polymeric in form. Thus the significance of the gold deposits observed is not clear. It
could either have a therapeutic action or be a detoxification step.
The lack of any clear transport and delivery function for gold in vivo leads to its
accumulation in most body tissues. High concentrations are obtained in such organs as
kidney, liver and spleen as well as in bones [2]. Lesser quantities are found in hair, nails
etc. One worrying feature of these gold distribution studies is that gold can be detected
long after the cessation of myocrisin therapy. Why the gold is present for such long
periods is not known but the likely explanation is that insoluble polymeric and unreactive
gold(l) complexes or gold(0) colloidal particles are accumulated. Gold(l) complexes are
usually favoured as the most likely storage form since the aurosomes found in the white
cells contain high sulphur concentrations as well as high gold concentrations.
REACTIONS OF GOLD COMPOUNDS
Myocrisin is a polymeric molecule known to occur with a number of different chain
lengths [11], all of which react readily with thiols [12] in complex degradation reactions.
These reactions are initiated by ligand substitution at the terminal thiolate gold bonds,
Which would appear to be less stable than the corresponding internal bridging thiolates.
For example, the reaction between cysteine and myocrisin [2] has been studied by
circular dichroism. It is clear from a kinetic study over a period of 2 days that a large
number of intermediate species are formed. The final product of the reaction is gold(I)
cysteine- an insoluble gold polymer. Prior to its formation, a very strong dichroism signal
is obtained indicating the increasing rigidity of the species formed. Other thiols which
have been tested and found to react include glutathione, and penicillamine [12].
The nature of the reactive site in albumin has been investigated in many studies. The
main site being that present at cysteine 34. The question arises as to how many gold
atoms remain on the sulphur. In essence, the polymeric myocrisin species has to enter a
pocket on the albumin where the reaction occurs and there is no guarantee of complete
breakdown of the polymer. Alternatively, the reaction involves transport of a fragment of
the polymer obtained by substitution reactions analogous to these described above. It
must be remembered that in-vivo albumin is present as a heterogeneous protein which
comprises of three forms: the free sulphydryl form (cysteine 34), a mixed disulphide
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formed between cysteine 34 and cysteine and a mixed disulphide formed between
cysteine 34 and glutathione all of which are potential sites for gold activity.
In vitro, in incubation studies of myocrisin and albumin, the total gold concentration in
albumin rises to a maximum of one gold atom per available sulphydryl residue at
cysteine 34 [13]. The amount of gold incorporated into the protein can be increased by
the addition of glutathione to the gold albumin mixture. It is believed that the addition of
glutathione to the mixture facilitates the reduction of either the glutathione mixed
disulphide or more probably the cysteine mixed disulphide, and this leads to a higher
than expected incorporation of gold in the protein. Them is little evidence to support the
formation of a second gold binding site which can bind gold strongly and it would seem
that the loosely bound gold identified in the gel permeation [2] studies arises from
absorption of unchanged myocrisin into a pocket in the protein. Them could in addition
be a weak association of the gold at other locations on the protein such as the copper or
nickel binding site which contains a ligand set not entirely compatible with the soft metal
ions.
That a significant amount of myocrisin quickly associates with albumin and that a
significant fraction of the metal clears from the plasma pool between injections [2] has
led to suggestions that in the therapeutic action of gold in rheumatoid arthritis, the
albumin gold complex is somehow involved either in metal transportation or as a "buffer"
by accepting gold in the plasma and releasing it in the synovial cavity. Although many
studies can show efficient and stoichiometric incorporation of gold into albumin, the
reverse reaction is more difficult and requires a ligand such as CN or RS which can
penetrate into the pocket containing cysteine-34 and compete for the metal ion [14,15].
Although the reactions between albumin and myocrisin are relatively rapid and occur
over a period of a few hours, it is more difficult to obtain an interaction between gold and
,-globulin. That this occurs in vivo is clearly evidenced by the distribution studies. In
vitro, following incubation over a period of 24 hours, appreciable amounts of gold are
found to be bound to this protein [13]. The amount of gold incorporated is postulated to
achieve a value commensurate with one gold atom per protein molecule. However, in
contrast to albumin, l-globulin does not react with thiol specific reagents and shows no
evidence of a free thiol group. Thus an analogous reaction to the interaction of myocrisin
with cysteine 34 on albumin cannot be occurring. The reaction of myocrisin with ,-
globulin and the effect of glutathione on albumin/myocrisin incubations prompted the
question of whether myocrisin would react appreciably with disulphides in-vivo. In-vitro
this was first shown using lipoic acid and EIImans reagent [16]. The rate of reaction is
slower than with thiols but is appreciable and varies significantly depending on the
nature of the disulphide. This work has been considerably extended more recently,
indicating that gold disulphide reactions are a distinct probability in in vivo situations. ,-
Globulin has more reactive disulphides close to the swing region and reaction with these
protein sites is already known for other species. Thus, it is postulated that the most likely
source of reaction between /-globulin and myocrisin is by reaction at these high energy
disulphide sites. Preliminary experiments in this area indicate that the protein after
prolonged incubation can be broken into smaller fractions [17]. This reaction itself is
important and has been very little studied. The mason for its importance lies in the direct
relationship between f-globulin and immunological response. Antigens are polymerised
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globulins. A metal induced conformational change in /-globulin as a consequence of
gold therapy may directly involve myocrisin in immune regulation in arthritis.
The sulphydryl status of platelets is similar to that of the globulins in that they have no
appreciable sulphydryl concentration on the outer surface as determined by EIImans
reagent. However, preliminary studies [18] using high levels of gold have shown that
platelet activation is affected by myocrisin in-vitro. Due to the low myocrisin
concentration administered clinically it is unlikely that this is a primary effect of gold in-
vivo. However, it is likely that this action may be occurring via a disulphide interaction
rather than via a thiolate interaction. It can be difficult in cell studies to differentiate
between the two targets, sulphydryl and disulphide, and as a sulphydryl free model of a
specific type of myocrisin chemistry the globulins and platelets deserves to be studied in
more in depth.
INTERACTION OF GOLD WITH ENZYMES AND CELLS
In addition to reactions of gold(I) with thiols, disulphides and other soft ligands such as
selenium and nitrogen donors, gold has a potentially important redox chemistry.
Although gold(Ill) has a high redox value and the oxidation of gold(I) to gold(Ill) is not
easy, it can be accomplished in the presence of hypochlorite, one of the oxidants
produced by phagocytic cells. Thus, in specific sites and under the correct chemical
conditions it may be possible for gold(Ill) to play a part in the mechanism of action (see
articles by Gleichmann and Shaw). Most gold(Ill) compounds formed are halide or
nitrogen compounds. For example, a stable gold(Ill) penicillamine complex is relatively
easy to produce [19]. It is more difficult to produce such compounds with cysteine but
the micro environments present throughout the body could lead to specific sites where
gold(Ill) is stable. In any event, the transient formation of gold(Ill) could enable targeted
redox reactions at donor sites of biological significance such as enzyme or transcriptase
sites. Other papers in this series will develop this theme indicating that such activity
does indeed occur. An additional reaction that should be borne in mind is the well known
fact that in the absence of stabilising ligands such as thiols and cyanide, gold(Ill) and
gold(I) species are very readily reduced to gold(0). For example, the reaction of gold(Ill)
in the form of tetrachloroaurate(lll) with alanine produces gold(0) colloid and
acetaldehyde [2]. Gold colloid in its finely divided form, can relatively easily be re-
oxidised to both gold (I) and gold(Ill) using sulphur compounds [2]. Thus, the
precipitation of gold(0) at some point in in vitro chemistry could lead to gold(0) deposition
but equally, could be a transitory species re-oxidised in the presence of oxidants such
as hypochlorite.
A wide ranging survey of the action of gold compounds on enzymes indicated that many
can be affected. However, them was no strong evidence that any one enzyme was
selectively affected and hence would provide a possible mechanism for the clinical
action of myocrisin. Glutathione peroxidase has long been suspected of being an
enzyme that may be affected [20]. The selenium atom (pK, <7) at the active site of
glutathione peroxidase is soft and may react with myocrisin leading to significant
changes its action. This enzyme is present in a number of fractions including the
plasma and the red cell cytosol. In an initial study of the activity of glutathione
pemxidase following myocrisin treatment, it was found that very significant inhibition of
both plasma and red cell glutathione peroxidase activity was apparent in patients treated
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with myocrisin compared to a group of patients being treated with NSAID’s [21]. Thus,
there is some in vivo rational for further studies of this enzyme. However, in-vivo
glutathione pemxidase does not operate in isolation but as a component of a larger
system involved in glutathione regulation. Here it must operate in concert with other
enzymes such a synthase and reductase and a number of co-factors e.g. NADPH and
glutathione. Thus although the clinical data suggests that gold inhibits glutathione
pemxidase there may be other effects on the glutathione cycle, which affect the
sulphydryl balance of the cell.
Many studies discuss the ability of myocrisin to interact directly with glutathione within
biological systems and the recent paper in this volume by Tepperman et al. shows that
this gold-glutathione species may form inside the cell. Glutathione reductase is yet
another example of an enzyme which contains a sulphydryl residue at its active site.
However,. in contrast to peroxidase which has an accessible selenium binding site, it
would seem that gold moieties are excluded from binding to the active site of glutathione
reductase as there is little inhibition of this enzyme by either myocrisin or auranofin. This
was confirmed by the use of small thiolates in the system. Mixed disulphides of
glutathione with penicillamine, captopril and N-acetylcysteine are not recognised by
glutathione reductase. Whereas it has long been known that glutathione peroxidase will
be affected by myocrisin therapy [20], the greater impact of gold on the glutathione cycle
has not been fully appreciated. The impact of down regulation of the peroxidase (GSH
consumption) in the face of an active reductase (GSH production) leading to an
alteration in the redox balance of the cell will be discussed below.
The gold to thiol ratio in plasma is such that the albumin thiol site cannot be saturated
and it is difficult to explain the efficacy of gold on the basis of an interaction with the
plasma proteins. Intracellularly, the concentration of glutathione, the major small thiol
present in the cytosol is higher than that of gold by orders of magnitude. Thus, in the red
cell and other cell types containing a significant concentration of glutathione, the thiol
concentrations present exceed that of gold. Them is no evidence at present that any
one small and active thiol fraction in the cytosol is inhibited to such an extent as to
suggest a unique action for gold. However, this does not apply to the cell membrane,
where approximately the same number of free reactive thiols and gold atoms are
present [5,8]. Since these quantities are very difficult to estimate, this calculation is liable
to considerable error but it does indicate the possibility of saturation at cell membrane
sites.
On the red cell membrane, the thiol groups are distributed quite widely [22] but two
proteins provide the largest single concentrations of reactive thiol on the plasma
(exofacial) side of the membrane of the intact cell. About 60% of the thiol groups are
present on the hexose transport protein. This corresponds to two thiol groups per protein
(cysteine 421 & 429) which are exposed to the plasma surface during glucose binding
and transport and .are thus available to bind soft metals (e.g. gold and mercury). The
second largest fraction is found on the anion transporter. This protein controls water
balance in the cell and chloride/carbonate exchange. This particular protein accounts
for about 13% of the available reactive thiol. Again the conformation plays a significant
role as to whether or not the thiol group is exposed to the plasma surface.
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One method of detecting the thiol groups on the membrane is by incubation with
EIImans reagent, a disulphide. This produces a coloured anion capable of detection by
electronic or Raman spectroscopy. In a clinical study of erythrocyte membrane it was
possible to show that gold does bind to the exofacial surface of the cell wall [8]. The
study indicates that them are at least two possible binding sites, including one on the
hexose transporter. The ability to detect cysteine 421 & 429 on the transporter
disappears in the presence of gold. However them is a general depression in the
membrane thiol concentration which suggests that other sites are also affected. Recent
studies [6, 23] indicate that in-vivo transport of gold as [Au(CN)ff is possible facilitating
the binding of gold at a protein on the intracellular face of the membrane (spectrin?).
Complexation of a metal to the functional groups at the cell wall would be expected to
affect cell biochemistry via a direct modulation of transport protein activity or as a
consequence of transmembrane signalling processes.
The activity of the cell surface sulphydryl functions is altered. In-vitro, erythrocytes
incubated with myocrisin and treated subsequently with EIImans reagent indicate that
the activity of the membrane thiols is little affected by gold incubation [24]. However, on
further incubation with EIImans reagent, the reaction shows a clear diminution of the
amount of anion resulting from exchange of the disulphide with the membrane thiol. It is
clear from a number of studies that if the exofacial thiols are oxidised, the cell
regenerates them. The reaction with gold treated cells suggests that the effect of the
EIImans anion is to cause a reaction involving gold bound to other thiols or disulphides
deeper in the protein structure.
Treatment of red cells exofacially with thiophillic agents causes an immediate response
in the cytosol. In essence, the intracellular glutathione becomes more oxidised and as
the reaction continues the concentration of glutathione is reduced. These reactions are
unlikely to be due to a stoichiometric reaction between glutathione and gold since the
glutathione concentration is too high and the amount of gold cyanide present for
transport purposes would be minimal in these in-vitro experiments. The most likely
reason for such reactions is that the gold initially affects cell membrane and a
transmembrane stimulus affects the thiol group. Experiments with many other thiol
active compounds have since been carried out. Similar but not identical responses to
intracellular glutathione have been obtained. Again the reaction is not stoichiometric
and in some cases, for example with EIImans reagent, the reagents used are believed to
be cell membrane impermeant. Thus, the likelihood of a transmembrane oxidative
stress created by thiols and thiophillic agents such as gold seems quite high.
The studies above are concerned with transmembrane redox balance. However, the
proteins being targeted are functionally active. Our preliminary study [25] focused on the
hexose transporter which is found to be subtly altered by gold. The transport of and
glucose across the membrane was followed by 13-C NMR spectroscopy. 3 glucose
transport involves a conformational change in the sugar transporter whereas o glucose
does not. The rate of transport of a glucose molecule is very quick and much faster
than the rate of glucose anomerisation. Thus it was difficult to measure by NMR the
early stages of the kinetics but the transport of each anomer could be followed
separately. That them was some control over the system was shown by the effect of the
specific blocking agent cytochalasin B. In the presence of cytochalasin B the uptake of
both <-glucose and I-glucose slows down. In the presence of gold however, the
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transport of -glucose would seem to be relatively unaffected whereas the transport of
13-glucose is. It would seem that rather than the rate being affected gold somehow alters
the equilibrium position of the nutrient balance i.e. it elevates the concentration of I-
glucose. A simple explanation of this observation would be that complexation of gold to
the two cysteinyl residues on the exofacial surface moderates the conformational
change in the protein preventing the efflux of I-glucose. As the anomerisation reaction
is slow compared to transport the effective glucose concentration inside the cell is
increased. The action on a red cell is unlikely to be critical. However, similar proteins
involved in other processes such as calcium regulation will be present on monocytes
and other leukocytes. These proteins are required for functions particularly in situations
such as the respiratory burst where considerable energy changes occur. The
moderation of the action of the cell by Myocrisin could well be a key effect in vivo. Thus,
the red cell is a suitable model for initial studies but further studies are required using
the correct white cell fractions to discover whether incubation of gold alters transport
function and whether there is a link between this transport function and immune
modulation.
The studies above demonstrate the widespread distribution of gold in the cells and
proteins and indicate that cell function may be altered. Plasma proteins and erythrocytes
are excellent models but their function in the disease process is limited. Of more
importance are the peripheral white cells which includes the monocyte. In a recent study
[21], monocytes were isolated from patients treated with NSAIDs or myocrisin and
assayed for hydrogen peroxide production. The levels found were higher in the gold
treated patients than in controls (NSAID’s and normal volunteers) but were not elevated
to the extent that the cells could be classified as activated. Earlier in the discussion it
was pointed out that inhibition of glutathione pemxidase in cells would lead to an
increase in the amount of hydrogen peroxide in the cell and this could be a rationale for
this finding. That the hydrogen peroxide levels are not at levels indicative of activation is
because the other oxidant defence enzymes, such as catalase will not be affected.
Confirmation of this hypothesis rests in the estimation of glutathione reductase activity.
In these samples elevated reduced glutathione and depressed oxidised glutathione is
observed indicative of a perturbation in glutathione regulation by gold compounds.
CONCLUSIONS
The elucidation of the mechanism of action of gold complexes in vivo has proved an
elusive target for many years. Recent developments have shown that a number of
promising lines of investigation are now opening up. Not all these lines of investigation
are described here since they are covered elsewhere in this series. However, they do
not all point in the same direction. From a practical point of view, the main advantage of
understanding the mechanism of action would be to improve the therapeutic to toxic
ratio of gold compounds and to provide more selective therapy. If a significant
improvement of this type could be achieved, the use of gold compounds in arthritis
would become much more widespread. From this point of view, more than one effect
may well be involved. For example, an understanding of a particular set of reactions
which lead to a reduction in toxic side effects could well prove important.
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The studies reviewed earlier indicate that any gold introduced into the body quickly
becomes complexed to proteins and cells. Unless them is a labile fraction on any of
these sites, the efficacy of myocrisin would depend on that small fraction of the gold
which interacts with the key site in competition with the plethora of other non-active
sites. Alternatively the efficacy and toxicity of gold may arise from its ability to act at a
number of sites affecting the delicate balance of the biochemistry of the cell, altering
cell function and cell-cell recognition mechanisms.
Of the ideas discussed in this document, two seem to have particular merit. The ability
of gold to interact at functionally active transport proteins in cell membrane suggests one
mechanism whereby gold can modulate the behaviour of cells. Thus, although the
erythrocyte can only be regarded as a model cell type in these experiments it would
seem that it is possible to alter the nutritional status of cells, for example, by altering the
equilibrium position of glucose across the cell wall via complexation of gold to
membrane sites. This may prepare cells for an increase in metabolism to offset
additional stress associated with the oxidative pathology of the disease. The action of
gold on the membrane would also seem to be important in redox signalling processes
suggesting that the membrane of the cell and the proteins embedded in it are one of the
key sites for gold action. For example cell fragility is a major consequence of the disease
process. This is membrane effect resulting from membrane oxidation (e.g. sulphydryl
functions on spectrin?) or from an imbalance in the flux of water across the cell wall (via
the anion transporter?.). Initial investigations of these sites indicate that these are targets
for agents such as gold and small thiolates [2].
The second concept is based on the observation that the glutathione peroxidase is
significantly affected by myocrisin both in vitro and in vivo. This leads to a small but
significant increase in hydrogen peroxide in the system and induces an alteration in the
oxidation reduction balance of the cell by elevating reduced glutathione and depleting
oxidised glutathione. Gold is ineffective in acute inflammation and active in chronic
inflammation. Chronic inflammation involves the accumulation of cells and interactions
between cells. For example, the macrophage requires a cuff of T and B cells to be
effective in chronic inflammation and the balance of T and B cell types is also a critical
factor. It is becoming apparent that species such as hydrogen peroxide and the
superoxide anion are used by some cells as signalling molecules [26]. One interpretation
of this data is that gold modulates these signals by altering the oxidant levels in the
synovium, thus altering the communication processes occurring between the
macrophage, B cells and T cells. A greater understanding of the signalling mechanisms
between cells based on chemical messengers like hydrogen peroxide may be critical to
understand this mechanism. Effects of this type and the triggering of additional oxidant
activity can both act as signalling systems and may provide a link between mechanisms
involving cell membrane and those involving intracellular components.
Recent experiments on thiol compounds [27,28] offer another way of exploring gold
biochemistry. Blood samples are separated to provide a monocyte fraction and red
cells. The monocytes are stimulated to produce hydrogen peroxide and then
recombined with the red cells in such a way that an increase in the white cell population
of a factor of 10-20 is achieved. This mixture enables white cell to red cell interactions
to be investigated. The white cell provides the active oxidant (HzO) which may be
involved in inflammatory responses and the red cell provides a target present in
505VoL 1, Nos. 5-6, 1994 Distribution and Reactivity ofMyocrisin
sufficient quantities for NMR signals to be recognised. The basic experiment is to induce
oxidation of the erythrocyte glutathione via the interaction of oxidants produced from the
active white cell. The action of gold in the system has yet to be investigated but other
thiol compounds such as penicillamine, captopril and N-acetylcysteine have a very
specific effect. In the absence of monocytes both penicillamine and captopril alter the
redox status of the erythrocyte to a more oxidised state. However, when active
monocytes are present it would seem that penicillamine and captopril protect the
erythrocyte from oxidation. The erythrocyte glutathione remains substantially unchanged
and the small thiols undergo sacrificial oxidation. In the presence and absence of
monocytes N-acetylcysteine will induce a redox shift in the erythrocytes to a more
reduced state. This is because N-acetylcysteine has two functions in this system. One
which alters the redox balance of the erythrocyte to a more reduced state and one which
switches off active monocytes stemming the flow of oxidants. Although these species
are all thiols they have substantially different effects on the cell and more importantly on
cell cell interactions.
Thus, at the present moment a number of different ideas are being pursued in different
places and it is to be hoped these activities will lead to a more definitive understanding
of the mechanism of action of gold.
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